Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]

BACKGROUND: Chronic psoriasis can negatively affect patients' lives. Assessing the impact of treatment on different aspects of a patient's health-related quality of life (HRQOL) is therefore important and relevant in trials of anti-psoriasis agents. The recombinant humanized IgG(1 )monoclo...

Descripción completa

Detalles Bibliográficos
Autores principales: Ortonne, Jean-Paul, Shear, Neil, Shumack, Stephen, Henninger, Eric
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1343580/
https://www.ncbi.nlm.nih.gov/pubmed/16359548
http://dx.doi.org/10.1186/1471-5945-5-13

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1343580/
https://www.ncbi.nlm.nih.gov/pubmed/16359548
http://dx.doi.org/10.1186/1471-5945-5-13

Ejemplares similares